Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva
This article was originally published in The Pink Sheet Daily
Executive Summary
Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.
You may also be interested in...
Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start
Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.
AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine
Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.
AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine
Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.